Lisa A. Robinson
Research Subjects
Lisa A. Robinson has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
James K. Hammitt
Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA
19 shared publications- James K. Hammitt
Center for Risk Analysis Harvard University Boston MA USA
4 shared publications - Lucy O’kEeffe
Harvard University, Center for Health Decision Science and Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, USA
2 shared publications - Maureen L. Cropper
University of Maryland - Department of Economics; Resources for the Future
2 shared publications Michael R. Eber
Harvard T.H. Chan School of Public Health Harvard University Boston Massachusetts USA
2 shared publicationsAlan Krupnick
Resources for the Future
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 16 (S2) , 152-158
Letter from Former SBCA Presidents and JBCA Editors to OIRA Administrator
- 27 November 2025
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 16 (S2) , 152-158
Open AccessLetter from Former SBCA Presidents and JBCA Editors to OIRA Administrator
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Environmental Epidemiology
- Vol. 9 (4) , e404
Health and economic benefits of energy, urban planning, and food interventions that lower greenhouse gas emissions
Public health can be immediately and substantially improved by policies that also mitigate climate change over the longer term. However, implementation of these policies has been slowed at least in part by doubts and lack of awareness of these health co-benefits. To address this barrier to progress, we demonstrate how an illustrative set of interventions led to environmental, health, and economic benefits, in addition to mitigating climate change. These case studies include the closure of a coal coking plant near Pittsburgh, PA, USA, which was followed by substantial immediate and longer-term reductions in respiratory and cardiovascular health conditions in the affected local community; the health and economic benefits associated with the Barcelona, Spain Superblock program and, the air quality, health, and economic benefits from air pollution initiatives implemented in China. While improvements in air pollution are among the most obvious examples of the co-benefits achievable through climate-friendly interventions, others that reduce greenhouse gas emissions, such as the sustainable food systems in Sweden, forest conservation in Tanzania, and a plant-based food program in New York City, further illustrate how such initiatives can align with better nutrition, economic gains, and improved health. We conclude that more assessments of such interventions are needed internationally to more widely document their health and climate benefits and thereby motivate greater implementation of these interventions. Now is the time to showcase how we can improve the public’s health and well-being, while also protecting our planet, the only home future generations will have.
- 1 July 2025
- Published by Wolters Kluwer Health in Environmental Epidemiology
- Vol. 9 (4) , e404
Open AccessHealth and economic benefits of energy, urban planning, and food interventions that lower greenhouse gas emissions
Public health can be immediately and substantially improved by policies that also mitigate climate change over the longer term. However, implementation of these policies has been slowed at least in part by doubts and lack of awareness of these health co-benefits. To address this barrier to progress, we demonstrate how an illustrative set of interventions led to environmental, health, and economic benefits, in addition to mitigating climate change. These case studies include the closure of a coal coking plant near Pittsburgh, PA, USA, which was followed by substantial immediate and longer-term reductions in respiratory and cardiovascular health conditions in the affected local community; the health and economic benefits associated with the Barcelona, Spain Superblock program and, the air quality, health, and economic benefits from air pollution initiatives implemented in China. While improvements in air pollution are among the most obvious examples of the co-benefits achievable through climate-friendly interventions, others that reduce greenhouse gas emissions, such as the sustainable food systems in Sweden, forest conservation in Tanzania, and a plant-based food program in New York City, further illustrate how such initiatives can align with better nutrition, economic gains, and improved health. We conclude that more assessments of such interventions are needed internationally to more widely document their health and climate benefits and thereby motivate greater implementation of these interventions. Now is the time to showcase how we can improve the public’s health and well-being, while also protecting our planet, the only home future generations will have.
- Open Access
- 13 May 2025
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 16 (S2) , 191-206
Guidance Is Not Enough: U.S. Circular A-4, “Regulatory Analysis”
Under President Clinton’s Executive Order 12866, “Regulatory Planning and Review,” U.S. federal agencies have been required to assess the costs, benefits, and other impacts of their major regulations since 1993. The U.S. Office of Management and Budget (OMB), in the Executive Office of the President, is responsible for overseeing this process and issuing related guidance. Under the Biden Administration, in April 2023 OMB issued a draft update of its 2003 Circular A-4 best-practice guidance and requested public comment. That update was finalized in November 2023, then rescinded by the Trump Administration in January 2025. This special issue of the Journal of Benefit-Cost Analysis provides reflections on the revisions of that guidance from past Society for Benefit-Cost Analysis presidents and Journal editors. Although I address several substantive issues in my comments and other work, barriers to implementation of best practices remain a major concern. Most of those who commented on the proposed revisions focused largely on the words on the page rather than on the work needed to implement them. Yet one of the most important sentences in both original and revised Circulars reads: “You will find that you cannot conduct a good regulatory analysis according to a formula. Conducting high-quality analysis requires competent professional judgment…” The challenge is supporting the development of this judgment, and ensuring that analysts have the data and resources necessary to conduct high-quality analyses that are useful for decision-making.
- 13 May 2025
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 16 (S2) , 191-206
Open AccessGuidance Is Not Enough: U.S. Circular A-4, “Regulatory Analysis”
Under President Clinton’s Executive Order 12866, “Regulatory Planning and Review,” U.S. federal agencies have been required to assess the costs, benefits, and other impacts of their major regulations since 1993. The U.S. Office of Management and Budget (OMB), in the Executive Office of the President, is responsible for overseeing this process and issuing related guidance. Under the Biden Administration, in April 2023 OMB issued a draft update of its 2003 Circular A-4 best-practice guidance and requested public comment. That update was finalized in November 2023, then rescinded by the Trump Administration in January 2025. This special issue of the Journal of Benefit-Cost Analysis provides reflections on the revisions of that guidance from past Society for Benefit-Cost Analysis presidents and Journal editors. Although I address several substantive issues in my comments and other work, barriers to implementation of best practices remain a major concern. Most of those who commented on the proposed revisions focused largely on the words on the page rather than on the work needed to implement them. Yet one of the most important sentences in both original and revised Circulars reads: “You will find that you cannot conduct a good regulatory analysis according to a formula. Conducting high-quality analysis requires competent professional judgment…” The challenge is supporting the development of this judgment, and ensuring that analysts have the data and resources necessary to conduct high-quality analyses that are useful for decision-making.
- Open Access
- 20 May 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (22)
Adopting electric school buses in the United States: Health and climate benefits
Electric school buses have been proposed as an alternative to reduce the health and climate impacts of the current U.S. school bus fleet, of which a substantial share are highly polluting old diesel vehicles. However, the climate and health benefits of electric school buses are not well known. As they are substantially more costly than diesel buses, assessing their benefits is needed to inform policy decisions. We assess the health benefits of electric school buses in the United States from reduced adult mortality and childhood asthma onset risks due to exposure to ambient fine particulate matter (PM 2.5 ). We also evaluate climate benefits from reduced greenhouse-gas emissions. We find that replacing the average diesel bus in the U.S. fleet in 2017 with an electric bus yields $84,200 in total benefits. Climate benefits amount to $40,400/bus, whereas health benefits amount to $43,800/bus due to 4.42*10 −3 fewer PM 2.5 -attributable deaths ($40,000 of total) and 7.42*10 −3 fewer PM 2.5 -attributable new childhood asthma cases ($3,700 of total). However, health benefits of electric buses vary substantially by driving location and model year (MY) of the diesel buses they replace. Replacing old, MY 2005 diesel buses in large cities yields $207,200/bus in health benefits and is likely cost-beneficial, although other policies that accelerate fleet turnover in these areas deserve consideration. Electric school buses driven in rural areas achieve small health benefits from reduced exposure to ambient PM 2.5 . Further research assessing benefits of reduced exposure to in-cabin air pollution among children riding buses would be valuable to inform policy decisions.
- 20 May 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (22)
Open AccessAdopting electric school buses in the United States: Health and climate benefits
Electric school buses have been proposed as an alternative to reduce the health and climate impacts of the current U.S. school bus fleet, of which a substantial share are highly polluting old diesel vehicles. However, the climate and health benefits of electric school buses are not well known. As they are substantially more costly than diesel buses, assessing their benefits is needed to inform policy decisions. We assess the health benefits of electric school buses in the United States from reduced adult mortality and childhood asthma onset risks due to exposure to ambient fine particulate matter (PM 2.5 ). We also evaluate climate benefits from reduced greenhouse-gas emissions. We find that replacing the average diesel bus in the U.S. fleet in 2017 with an electric bus yields $84,200 in total benefits. Climate benefits amount to $40,400/bus, whereas health benefits amount to $43,800/bus due to 4.42*10 −3 fewer PM 2.5 -attributable deaths ($40,000 of total) and 7.42*10 −3 fewer PM 2.5 -attributable new childhood asthma cases ($3,700 of total). However, health benefits of electric buses vary substantially by driving location and model year (MY) of the diesel buses they replace. Replacing old, MY 2005 diesel buses in large cities yields $207,200/bus in health benefits and is likely cost-beneficial, although other policies that accelerate fleet turnover in these areas deserve consideration. Electric school buses driven in rural areas achieve small health benefits from reduced exposure to ambient PM 2.5 . Further research assessing benefits of reduced exposure to in-cabin air pollution among children riding buses would be valuable to inform policy decisions.
- Open Access
- 1 January 2024
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 15 (S1) , 1-5
Ethics and Benefit–Cost Analysis: Introduction to the Special Issue
Conventional benefit–cost analysis plays an important role in informing policy decisions, encouraging systematic investigation of the positive and negative impacts of alternative policies. It is based on strong normative assumptions, however. To measure individual wellbeing, the conventional approach relies on individuals’ willingness to exchange their income for the outcomes they experience. To measure societal welfare, it relies on simple aggregation of these values across individuals. In this “Ethics and Benefit–Cost Analysis” special issue, we explore alternative conceptions of individual and societal welfare, their application, and the implications, from both practical and ethical perspectives.
- 1 January 2024
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 15 (S1) , 1-5
Open AccessEthics and Benefit–Cost Analysis: Introduction to the Special Issue
Conventional benefit–cost analysis plays an important role in informing policy decisions, encouraging systematic investigation of the positive and negative impacts of alternative policies. It is based on strong normative assumptions, however. To measure individual wellbeing, the conventional approach relies on individuals’ willingness to exchange their income for the outcomes they experience. To measure societal welfare, it relies on simple aggregation of these values across individuals. In this “Ethics and Benefit–Cost Analysis” special issue, we explore alternative conceptions of individual and societal welfare, their application, and the implications, from both practical and ethical perspectives.
- Open Access
- 1 January 2024
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 15 (S1) , 84-109
From Benefit–Cost Analysis to Social Welfare: A Pragmatic Approach
Conventional benefit–cost analysis is well-established and widely used to assess interventions designed to improve public health and welfare. While it has many advantages, it has well-known limitations. Chief among these is its inattention to the distributional equity of the impacts. To measure individual well-being, the conventional approach relies on individuals’ willingness to exchange their own income for the outcomes they experience. To measure societal welfare, it relies on simple aggregation of these values across individuals. This approach reflects a relatively narrow conception of welfare and ignores how impacts are distributed across advantaged and disadvantaged individuals. Social welfare analysis has been proposed as an alternative approach to address these limitations, but real-world applications are rare due largely to the complexity of the calculations. This article provides a pragmatic approach for conducting equity-sensitive benefit–cost analysis globally that addresses data limitations and other challenges, illustrated with example applications. It formally develops and implements equity weights that adjust for the decreasing marginal value of money and for additional moral considerations, prioritizing increases in welfare for those who are worse off.
- 1 January 2024
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 15 (S1) , 84-109
Open AccessFrom Benefit–Cost Analysis to Social Welfare: A Pragmatic Approach
Conventional benefit–cost analysis is well-established and widely used to assess interventions designed to improve public health and welfare. While it has many advantages, it has well-known limitations. Chief among these is its inattention to the distributional equity of the impacts. To measure individual well-being, the conventional approach relies on individuals’ willingness to exchange their own income for the outcomes they experience. To measure societal welfare, it relies on simple aggregation of these values across individuals. This approach reflects a relatively narrow conception of welfare and ignores how impacts are distributed across advantaged and disadvantaged individuals. Social welfare analysis has been proposed as an alternative approach to address these limitations, but real-world applications are rare due largely to the complexity of the calculations. This article provides a pragmatic approach for conducting equity-sensitive benefit–cost analysis globally that addresses data limitations and other challenges, illustrated with example applications. It formally develops and implements equity weights that adjust for the decreasing marginal value of money and for additional moral considerations, prioritizing increases in welfare for those who are worse off.
- Open Access
- 1 January 2024
- Published by Elsevier in SSRN Electronic Journal
Economic Evaluation for Health Priority-Setting: Cost-Effectiveness Analysis and Benefit-Cost Analysis Primer
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence needed to support sound policy decisions. In low- and middle-income countries, where resources are especially scarce and needs are very great, such decisions are exceptionally difficult. In these settings, economic evaluation can be particularly useful in determining how to best improve health and welfare. Typically, cost-effectiveness analysis (CEA) is used to prioritize interventions within the health care sector. This approach involves comparing monetary costs to non-monetary measures of health impacts, focusing on how to best invest limited resources to maximize improvements in health. Outside the health care sector, benefit-cost analysis (BCA) is more often used. Under this approach, all impacts, including health, are valued in monetary terms. The focus is on investing to improve welfare more generally, including health and other aspects of wellbeing. Both approaches provide important and useful information, although each has limitations as well as advantages. This working paper introduces and summarizes these economic evaluation methods.
- 1 January 2024
- Published by Elsevier in SSRN Electronic Journal
Open AccessEconomic Evaluation for Health Priority-Setting: Cost-Effectiveness Analysis and Benefit-Cost Analysis Primer
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence needed to support sound policy decisions. In low- and middle-income countries, where resources are especially scarce and needs are very great, such decisions are exceptionally difficult. In these settings, economic evaluation can be particularly useful in determining how to best improve health and welfare. Typically, cost-effectiveness analysis (CEA) is used to prioritize interventions within the health care sector. This approach involves comparing monetary costs to non-monetary measures of health impacts, focusing on how to best invest limited resources to maximize improvements in health. Outside the health care sector, benefit-cost analysis (BCA) is more often used. Under this approach, all impacts, including health, are valued in monetary terms. The focus is on investing to improve welfare more generally, including health and other aspects of wellbeing. Both approaches provide important and useful information, although each has limitations as well as advantages. This working paper introduces and summarizes these economic evaluation methods.
- Open Access
- 17 January 2023
- Published by Wiley in Risk Analysis
- Vol. 43 (10) , 2053-2068
The benefits and costs of U.S. employer COVID‐19 vaccine mandates
In 2021, the Biden Administration issued mandates requiring COVID-19 vaccinations for U.S. federal employees and contractors and for some healthcare and private sector workers. These mandates have been challenged in court; some have been halted or delayed. However, their costs and benefits have not been rigorously appraised. This study helps fill that gap. We estimate the direct costs and health-related benefits that would have accrued if these vaccination requirements had been implemented as intended. Compared with the January 2022 vaccination rates, we find that the mandates could have led to 15 million additional vaccinated individuals, increasing the overall proportion of the fully vaccinated U.S. population from 64% to 68%. The associated net benefits depend on the subsequent evolution of the pandemic-information unavailable ex ante to analysts or policymakers. In scenarios involving the emergence of a novel, more transmissible variant, against which vaccination and previous infection offer moderate protection, the estimated net benefits are potentially large. They reach almost $20,000 per additional vaccinated individual, with more than 20,000 total deaths averted over the 6-month period assessed. In scenarios involving a fading pandemic, existing vaccination-acquired or infection-acquired immunity provides sufficient protection, and the mandates' benefits are unlikely to exceed their costs. Thus, mandates may be most useful when the consequences of inaction are catastrophic. However, we do not compare the effects of mandates with alternative policies for increasing vaccination rates or for promoting other protective measures, which may receive stronger public support and be less likely to be overturned by litigation.
- 17 January 2023
- Published by Wiley in Risk Analysis
- Vol. 43 (10) , 2053-2068
Open AccessThe benefits and costs of U.S. employer COVID‐19 vaccine mandates
In 2021, the Biden Administration issued mandates requiring COVID-19 vaccinations for U.S. federal employees and contractors and for some healthcare and private sector workers. These mandates have been challenged in court; some have been halted or delayed. However, their costs and benefits have not been rigorously appraised. This study helps fill that gap. We estimate the direct costs and health-related benefits that would have accrued if these vaccination requirements had been implemented as intended. Compared with the January 2022 vaccination rates, we find that the mandates could have led to 15 million additional vaccinated individuals, increasing the overall proportion of the fully vaccinated U.S. population from 64% to 68%. The associated net benefits depend on the subsequent evolution of the pandemic-information unavailable ex ante to analysts or policymakers. In scenarios involving the emergence of a novel, more transmissible variant, against which vaccination and previous infection offer moderate protection, the estimated net benefits are potentially large. They reach almost $20,000 per additional vaccinated individual, with more than 20,000 total deaths averted over the 6-month period assessed. In scenarios involving a fading pandemic, existing vaccination-acquired or infection-acquired immunity provides sufficient protection, and the mandates' benefits are unlikely to exceed their costs. Thus, mandates may be most useful when the consequences of inaction are catastrophic. However, we do not compare the effects of mandates with alternative policies for increasing vaccination rates or for promoting other protective measures, which may receive stronger public support and be less likely to be overturned by litigation.
- 3 August 2022
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 13 (2) , 247-268
Valuing COVID-19 Morbidity Risk Reductions
Many economic analyses, including those that address the COVID-19 pandemic, focus on the value of averting deaths and do not include the value of averting nonfatal illnesses. Yet, incorporating the value of averting nonfatal cases may change conclusions about the desirability of the policy. While per case values may be small, the number of nonfatal cases is often large, far outstripping the number of fatal cases. The value of averting nonfatal cases is also increasingly important in evaluating COVID-19 policy options as vaccine- and infection-related immunity and treatments reduce the case-fatality rate. Unfortunately, little valuation research is available that explicitly addresses COVID-19 morbidity. We describe and implement an approach for approximating the value of averting nonfatal illnesses or injuries and apply it to COVID-19 in the USA. We estimate gains from averting COVID-19 morbidity of about 0.01 quality-adjusted life year (QALY) per mild case averted, 0.02 QALY per severe case, and 3.15 QALYs per critical case. These gains translate into monetary values of about $1.8 million per critical case. While these estimates are imprecise, they suggest the magnitude of the effects.
- 3 August 2022
- Published by Cambridge University Press (CUP) in Journal of Benefit-Cost Analysis
- Vol. 13 (2) , 247-268
Valuing COVID-19 Morbidity Risk Reductions
Many economic analyses, including those that address the COVID-19 pandemic, focus on the value of averting deaths and do not include the value of averting nonfatal illnesses. Yet, incorporating the value of averting nonfatal cases may change conclusions about the desirability of the policy. While per case values may be small, the number of nonfatal cases is often large, far outstripping the number of fatal cases. The value of averting nonfatal cases is also increasingly important in evaluating COVID-19 policy options as vaccine- and infection-related immunity and treatments reduce the case-fatality rate. Unfortunately, little valuation research is available that explicitly addresses COVID-19 morbidity. We describe and implement an approach for approximating the value of averting nonfatal illnesses or injuries and apply it to COVID-19 in the USA. We estimate gains from averting COVID-19 morbidity of about 0.01 quality-adjusted life year (QALY) per mild case averted, 0.02 QALY per severe case, and 3.15 QALYs per critical case. These gains translate into monetary values of about $1.8 million per critical case. While these estimates are imprecise, they suggest the magnitude of the effects.
- 12 April 2021
- Published by Wiley in Risk Analysis
- Vol. 41 (4) , 559-564
Introduction to Special Issue on Risk Assessment, Economic Evaluation, and Decisions
Integrating risk assessment, economic evaluation, and uncertainty to inform policy decisions is a core challenge to risk analysis. In September 2019, the Harvard Center for Risk Analysis, with support from the Society for Risk Analysis Economics and Benefits Analysis Specialty Group and others, convened a workshop to address this issue. The workshop built in part on the recommendations of the 2009 National Research Council report, Science and Decisions: Advancing Risk Assessment. It honored John S. Evans, whose thoughtful and innovative teaching and scholarship have significantly advanced thinking on these issues. This special issue features a profile of Dr. Evans and nine articles that build on work presented at the workshop.
- 12 April 2021
- Published by Wiley in Risk Analysis
- Vol. 41 (4) , 559-564
Introduction to Special Issue on Risk Assessment, Economic Evaluation, and Decisions
Integrating risk assessment, economic evaluation, and uncertainty to inform policy decisions is a core challenge to risk analysis. In September 2019, the Harvard Center for Risk Analysis, with support from the Society for Risk Analysis Economics and Benefits Analysis Specialty Group and others, convened a workshop to address this issue. The workshop built in part on the recommendations of the 2009 National Research Council report, Science and Decisions: Advancing Risk Assessment. It honored John S. Evans, whose thoughtful and innovative teaching and scholarship have significantly advanced thinking on these issues. This special issue features a profile of Dr. Evans and nine articles that build on work presented at the workshop.